[1]Synthesis,2002,p.2387-2392
Title: Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
Journal: International journal of cancer 20121101
Title: A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors.
Journal: Anticancer research 20120501
Title: Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Journal: Investigational new drugs 20120201
Title: Cytostatic activity of the duplex drug linking 2'-deoxy-5-fluorouridine (5FdU) with 3'-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines.
Journal: Investigational new drugs 20111201
Title: ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.
Journal: Investigational new drugs 20110601
Title: Cellular pharmacology of multi- and duplex drugs consisting of ethynylcytidine and 5-fluoro-2'-deoxyuridine.
Journal: Investigational new drugs 20110401
Title: Acceptance of oral chemotherapy in breast cancer patients - a survey study.
Journal: BMC cancer 20110101
Title: RNA polymerase III transcription in cancer: the BRF2 connection.
Journal: Molecular cancer 20110101
Title: A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.
Journal: Molecular cancer 20110101
Title: Cytotoxicity and antileukaemic activity of new duplexes linking 3-C-ethynylcytidine and 5-fluorodeoxyuridine.
Journal: Anticancer research 20101201
Title: Association of RNase L with a Ras GTPase-activating-like protein IQGAP1 in mediating the apoptosis of a human cancer cell-line.
Journal: The FEBS journal 20101101
Title: An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.
Journal: Biochemical pharmacology 20100615
Title: Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Journal: Bioorganic & medicinal chemistry 20091001
Title: PK-PD modeling of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and the enhanced antitumor effect of its phospholipid derivatives in long-circulating liposomes.
Journal: International journal of pharmaceutics 20090730
Title: Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
Journal: Bioorganic & medicinal chemistry 20090701
Title: 1-(3-C-Ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), a novel potent inhibitor of RNA polymerase, potentiates the cytotoxicity of CDDP in human cancer cells both in vitro and in vivo.
Journal: International journal of oncology 20090501
Title: Role of RNase L in apoptosis induced by 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
Journal: Cancer chemotherapy and pharmacology 20090401
Title: Molecular mechanisms of apoptosis induced by 3'-ethynylcytidine.
Journal: Nucleic acids symposium series (2004) 20090101
Title: Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo.
Journal: British journal of cancer 20081104
Title: Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy.
Journal: Current medicinal chemistry 20080101
Title: In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine.
Journal: Nucleic acids symposium series (2004) 20080101
Title: Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides.
Journal: Cancer science 20071001
Title: Mechanism of action of a new antitumor ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106), differs from that of 5-fluorouracil.
Journal: Oncology reports 20070601
Title: Treatment combining X-irradiation and a ribonucleoside anticancer drug, TAS106, effectively suppresses the growth of tumor cells transplanted in mice.
Journal: International journal of radiation oncology, biology, physics 20070501
Title: A novel apoptotic pathway of 3'-Ethynylcytidine(ECyd) involving the inhibition of RNA synthesis--the possibility of RNase L activated pathway as a target of ECyd.
Journal: Nucleic acids symposium series (2004) 20070101
Title: An apoptotic pathway of 3'-Ethynylcytidine(ECyd) involving the inhibition of RNA synthesis mediated by RNase L.
Journal: Nucleic acids symposium series (2004) 20060101
Title: X irradiation induces the proapoptotic state independent of the loss of clonogenic ability in Chinese hamster V79 cells.
Journal: Radiation research 20050701
Title: Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Journal: Cancer science 20050501
Title: Synthesis and biological evaluation of branched and conformationally restricted analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).
Journal: Bioorganic & medicinal chemistry 20050401
Title: Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).
Journal: Bioorganic & medicinal chemistry 20050215
Title: Synthesis and biological evaluation of conformationally restricted and nucleobase-modified analogs of the anticancer compound 3'-C-ethynylcytidine (ECyd).
Journal: Nucleosides, nucleotides & nucleic acids 20050101
Title: A novel anticancer ribonucleoside, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine, enhances radiation-induced cell death in tumor cells.
Journal: Radiation research 20041201
Title: A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3'-ethynyl nucleosides.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20041001
Title: New nucleoside analogs in the treatment of solid tumors.
Journal: Acta poloniae pharmaceutica 20040101
Title: Synthesis of the cyclic and acyclic acetal derivatives of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine, a potent antitumor nucleoside. Design of prodrugs to be selectively activated in tumor tissues via the bio-reduction-hydrolysis mechanism.
Journal: Bioorganic & medicinal chemistry 20030529
Title: Determination of 3'-C-ethynylcytidine in human plasma and urine by liquid chromatographic-electrospray ionization tandem mass spectrometry.
Journal: Journal of pharmaceutical and biomedical analysis 20030205
Title: Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.
Journal: Japanese journal of cancer research : Gann 20020701
Title: Cellular and biochemical mechanisms of the resistance of human cancer cells to a new anticancer ribo-nucleoside, TAS-106.
Journal: Japanese journal of cancer research : Gann 20020401
Title: Analysis of single nucleotide polymorphisms in uridine/cytidine kinase gene encoding metabolic enzyme of 3'-ethynylcytidine.
Journal: Nucleic acids research. Supplement (2001) 20020101
Title: Anticancer mechanisms of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl) cytosine (ECyd, TAS-106).
Journal: Nucleic acids research. Supplement (2001) 20020101
Title: Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells.
Journal: International journal of molecular medicine 20010901
Title: An efficient method for the preparation of 1'alpha-branched-chain sugar pyrimidine ribonucleosides from uridine: the first conversion of a natural nucleoside into 1'-substituted ribonucleosides.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany) 20010601
Title: Improvement in precision of the liquid chromatographic-electrospray ionization tandem mass spectrometric analysis of 3'-C-ethynylcytidine in rat plasma.
Journal: Journal of chromatography. B, Biomedical sciences and applications 20010415
Title: Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
Journal: Japanese journal of cancer research : Gann 20010301
Title: 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)1: antitumor effect and mechanism of action.
Journal: Nucleosides, nucleotides & nucleic acids 20010101
Title: Anticancer molecular mechanism of 3'-ethynylcytidine (ECyd).
Journal: Nucleic acids research. Supplement (2001) 20010101
Title: Shimamoto Y, et al. Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine. Jpn J Cancer Res. 2001 Mar;92(3):343-51.
Title: Abdelrahim M, et al. TAS-106: preclinical, clinical and beyond. Oncology. 2013;85(6):356-363.
Title: Hammond-Thelin LA, et al. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Invest New Drugs. 2012;30(1):316-326.
